EP3096753A4 - Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits - Google Patents
Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits Download PDFInfo
- Publication number
- EP3096753A4 EP3096753A4 EP14864113.7A EP14864113A EP3096753A4 EP 3096753 A4 EP3096753 A4 EP 3096753A4 EP 14864113 A EP14864113 A EP 14864113A EP 3096753 A4 EP3096753 A4 EP 3096753A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- idolinyl
- hydroxamates
- indolyl
- neurodegenerative disorders
- cognitive deficits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908168P | 2013-11-24 | 2013-11-24 | |
PCT/US2014/067040 WO2015077685A1 (en) | 2013-11-24 | 2014-11-24 | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3096753A1 EP3096753A1 (en) | 2016-11-30 |
EP3096753A4 true EP3096753A4 (en) | 2017-07-05 |
Family
ID=53180246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14864113.7A Withdrawn EP3096753A4 (en) | 2013-11-24 | 2014-11-24 | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits |
Country Status (11)
Country | Link |
---|---|
US (1) | US9956202B2 (es) |
EP (1) | EP3096753A4 (es) |
JP (1) | JP2016537375A (es) |
KR (1) | KR20160079899A (es) |
CN (1) | CN106456606A (es) |
AU (1) | AU2014352716A1 (es) |
CA (1) | CA2931345A1 (es) |
MX (1) | MX2016006633A (es) |
RU (1) | RU2016125313A (es) |
TW (1) | TWI659017B (es) |
WO (1) | WO2015077685A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7302120B2 (ja) | 2015-10-27 | 2023-07-04 | タイペイ メディカル ユニバーシティ | 線維症疾患の治療及び/又は予防用インドリン誘導体 |
CN112135834A (zh) | 2018-06-27 | 2020-12-25 | 雅玛山酱油株式会社 | 3’,3’-cGAMP的水合物晶体 |
WO2023076150A1 (en) * | 2021-10-29 | 2023-05-04 | Psilera Inc. | Modified indole compounds |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110245315A1 (en) * | 2010-03-29 | 2011-10-06 | Taipei Medical University | Indolyl or indolinyl hydroxamate compounds |
WO2013040520A1 (en) * | 2011-09-15 | 2013-03-21 | Taipei Medical University | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury |
WO2013055386A2 (en) * | 2011-10-03 | 2013-04-18 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
WO2013150529A2 (en) * | 2012-04-02 | 2013-10-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Indole, indoline derivatives, compositions comprising them and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
JP2012510512A (ja) * | 2008-12-03 | 2012-05-10 | マサチューセッツ インスティテュート オブ テクノロジー | 記憶を推進するためのhdac2の阻害 |
-
2014
- 2014-11-24 CA CA2931345A patent/CA2931345A1/en not_active Abandoned
- 2014-11-24 WO PCT/US2014/067040 patent/WO2015077685A1/en active Application Filing
- 2014-11-24 EP EP14864113.7A patent/EP3096753A4/en not_active Withdrawn
- 2014-11-24 AU AU2014352716A patent/AU2014352716A1/en not_active Abandoned
- 2014-11-24 JP JP2016532061A patent/JP2016537375A/ja active Pending
- 2014-11-24 RU RU2016125313A patent/RU2016125313A/ru unknown
- 2014-11-24 TW TW103140738A patent/TWI659017B/zh not_active IP Right Cessation
- 2014-11-24 KR KR1020167016553A patent/KR20160079899A/ko not_active Application Discontinuation
- 2014-11-24 MX MX2016006633A patent/MX2016006633A/es unknown
- 2014-11-24 CN CN201480074066.3A patent/CN106456606A/zh active Pending
- 2014-11-24 US US15/038,671 patent/US9956202B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110245315A1 (en) * | 2010-03-29 | 2011-10-06 | Taipei Medical University | Indolyl or indolinyl hydroxamate compounds |
WO2013040520A1 (en) * | 2011-09-15 | 2013-03-21 | Taipei Medical University | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury |
WO2013055386A2 (en) * | 2011-10-03 | 2013-04-18 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
WO2013150529A2 (en) * | 2012-04-02 | 2013-10-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Indole, indoline derivatives, compositions comprising them and uses thereof |
Non-Patent Citations (3)
Title |
---|
CHUANG D M ET AL: "Multiple roles of HDAC inhibition in neurodegenerative conditions", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 32, no. 11, 1 November 2009 (2009-11-01), pages 591 - 601, XP026699543, ISSN: 0166-2236, [retrieved on 20090921], DOI: 10.1016/J.TINS.2009.06.002 * |
HSUEH-YUN LEE ET AL: "1-Arylsulfonyl-5-( N -hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY., vol. 14, no. 10, 20 June 2013 (2013-06-20), DE, pages 1248 - 1254, XP055371442, ISSN: 1439-4227, DOI: 10.1002/cbic.201300201 * |
See also references of WO2015077685A1 * |
Also Published As
Publication number | Publication date |
---|---|
RU2016125313A (ru) | 2017-12-28 |
US20160303079A1 (en) | 2016-10-20 |
WO2015077685A1 (en) | 2015-05-28 |
JP2016537375A (ja) | 2016-12-01 |
TW201609640A (zh) | 2016-03-16 |
US9956202B2 (en) | 2018-05-01 |
MX2016006633A (es) | 2016-12-02 |
CA2931345A1 (en) | 2015-05-28 |
EP3096753A1 (en) | 2016-11-30 |
TWI659017B (zh) | 2019-05-11 |
CN106456606A (zh) | 2017-02-22 |
AU2014352716A1 (en) | 2016-06-09 |
KR20160079899A (ko) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273688A (en) | Evaluation and treatment of bradykinin-mediated disorders | |
IL275720A (en) | Use of molecules that bind semphorin-D4 for the treatment of neurodegenerative disorders | |
EP3481387A4 (en) | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES | |
HK1214553A1 (zh) | 用於治療神經退行性疾病的拉喹莫德和普利多匹定 | |
IL241026A0 (en) | A head device for treating and evaluating medical conditions | |
EP2852388A4 (en) | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
EP2970317A4 (en) | PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES | |
IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
EP2983657A4 (en) | TREATMENT OF GASTROINTESTINAL AND OTHER DISEASES | |
EP3068492A4 (en) | Neurodegenerative disorders and methods of treatment and diagnosis thereof | |
EP3041577A4 (en) | Treatment and prevention of autism and autism spectrum disorders | |
EP3013342A4 (en) | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions | |
EP3052137A4 (en) | Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5 | |
EP2965085A4 (en) | METHODS AND SYSTEMS FOR DIAGNOSIS AND TREATMENT OF ANDROGENIC DISORDERS | |
HK1212897A1 (zh) | 使用穿心蓮內酯對阿爾茨海默氏病和認知缺損的治療 | |
EP3096753A4 (en) | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits | |
IL242297B (en) | Methods and treatment of certain disorders are based on the breakdown of myelin and the defective creation of myelin and/or the promotion of new creation of myelin | |
GB201411616D0 (en) | Diagnosis and treatment of neurodegenerative disorders | |
EP2999473A4 (en) | Treatment of neurological and other disorders | |
EP3074030A4 (en) | Method for mitigating or alleviating synaptic and cognitive deficits | |
AU2013901789A0 (en) | Treatment of Neurological and Other Disorders | |
AU2013901514A0 (en) | Formulation and methods for treatment of mental disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160613 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170607 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20170531BHEP Ipc: A61K 31/4365 20060101ALI20170531BHEP Ipc: A61K 31/37 20060101ALI20170531BHEP Ipc: A61K 31/355 20060101ALI20170531BHEP Ipc: A61K 31/616 20060101ALI20170531BHEP Ipc: A61K 31/404 20060101AFI20170531BHEP Ipc: A61K 31/04 20060101ALI20170531BHEP Ipc: C07D 209/40 20060101ALI20170531BHEP Ipc: A61K 31/122 20060101ALI20170531BHEP Ipc: A61K 31/519 20060101ALI20170531BHEP Ipc: A61K 45/06 20060101ALI20170531BHEP Ipc: A61K 31/375 20060101ALI20170531BHEP Ipc: A61P 25/00 20060101ALI20170531BHEP |
|
17Q | First examination report despatched |
Effective date: 20190709 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20191120 |